Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep41487
Abstract: Thiazolidinediones (TZD) function as potent anti-diabetic drugs through their direct action on the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ), but their therapeutic benefits are compromised by severe side effects. To address this concern, here… read more here.
Keywords: ppar; vsp; selective ppar; novel selective ... See more keywords
The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Research"
DOI: 10.1155/2020/4179852
Abstract: Purpose Peroxisome proliferator-activated receptor α (PPARα) plays a crucial role in the control of lipid homeostasis. Here, we investigated the effects of CP775146, a new selective PPARα agonist, on lipid metabolism in diet-induced obese mice… read more here.
Keywords: cp775146; selective ppar; lipid metabolism; new selective ... See more keywords
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1288
Abstract: OBJECTIVE High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The… read more here.
Keywords: ppar; pemafibrate selective; ppar modulator; 877 pemafibrate ... See more keywords
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
Sign Up to like & getrecommendations! Published in 2023 at "Metabolites"
DOI: 10.3390/metabo13050626
Abstract: Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events. However, these events cannot be fully prevented even when maintaining very low… read more here.
Keywords: ppar modulator; nonalcoholic fatty; pemafibrate; fatty liver ... See more keywords